Bavencio FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 28, 2021.
FDA Approved: Yes (First approved March 23, 2017)
Brand name: Bavencio
Generic name: avelumab
Dosage form: Injection
Company: EMD Serono, Inc.
Treatment for: Merkel Cell Carcinoma, Urothelial Carcinoma, Renal Cell Carcinoma
Bavencio (avelumab) is a programmed death ligand-1 (PD-L1) blocking antibody indicated for the treatment of patients with metastatic Merkel cell carcinoma (MCC); patients with advanced or metastatic urothelial carcinoma; and in combination with axitinib for patients with advanced renal cell carcinoma.
Development Timeline for Bavencio
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.